BioCentury | Nov 30, 2018
Company News

BioBlast merging with Enlivex

...BioBlast Pharma Ltd. (NASDAQ:ORPN) will merge with Enlivex Therapeutics Ltd. (Jerusalem, Israel), which is developing its Allocetra cell...
...muscular dystrophy and spinocerebellar ataxia type 3. The deal is slated to close next quarter. Enlivex Therapeutics Ltd....
...Pharma Ltd. (NASDAQ:ORPN), Tel Aviv, Israel Business: Transplant Shannon Lehnbeuter trehalose 90 mg/ml iv solution (cabaletta) BioBlast Pharma Ltd. Enlivex Therapeutics Ltd. Allocetra...
BioCentury | Apr 8, 2013
Clinical News

ApoCell regulatory update

...ApoCell uses autologous or donor cells manipulated ex vivo to begin early stages of apoptosis. Enlivex Therapeutics Ltd....
BioCentury | Feb 4, 2013
Financial News

Enlivex Therapeutics completes venture financing

Enlivex Therapeutics Ltd. , Jerusalem, Israel Business: Transplant, Gene/Cell therapy Date completed: 1/22/13 Type: Venture financing Raised: $268,000 Investor: Hadasit Bio-Holdings Note: The financing is a convertible loan. WIR Staff...
BioCentury | Nov 12, 2012
Clinical News

ApoCell: Phase I/II data

...ApoCell developed GvHD grades 2-4 compared to 50% of patients who did not receive ApoCell. Enlivex Therapeutics Ltd....
Items per page:
1 - 4 of 4
BioCentury | Nov 30, 2018
Company News

BioBlast merging with Enlivex

...BioBlast Pharma Ltd. (NASDAQ:ORPN) will merge with Enlivex Therapeutics Ltd. (Jerusalem, Israel), which is developing its Allocetra cell...
...muscular dystrophy and spinocerebellar ataxia type 3. The deal is slated to close next quarter. Enlivex Therapeutics Ltd....
...Pharma Ltd. (NASDAQ:ORPN), Tel Aviv, Israel Business: Transplant Shannon Lehnbeuter trehalose 90 mg/ml iv solution (cabaletta) BioBlast Pharma Ltd. Enlivex Therapeutics Ltd. Allocetra...
BioCentury | Apr 8, 2013
Clinical News

ApoCell regulatory update

...ApoCell uses autologous or donor cells manipulated ex vivo to begin early stages of apoptosis. Enlivex Therapeutics Ltd....
BioCentury | Feb 4, 2013
Financial News

Enlivex Therapeutics completes venture financing

Enlivex Therapeutics Ltd. , Jerusalem, Israel Business: Transplant, Gene/Cell therapy Date completed: 1/22/13 Type: Venture financing Raised: $268,000 Investor: Hadasit Bio-Holdings Note: The financing is a convertible loan. WIR Staff...
BioCentury | Nov 12, 2012
Clinical News

ApoCell: Phase I/II data

...ApoCell developed GvHD grades 2-4 compared to 50% of patients who did not receive ApoCell. Enlivex Therapeutics Ltd....
Items per page:
1 - 4 of 4